WO2017116358A1 - Procédé et appareil de détermination de marqueurs d'acides gras par mesure d'impédance électrique - Google Patents

Procédé et appareil de détermination de marqueurs d'acides gras par mesure d'impédance électrique Download PDF

Info

Publication number
WO2017116358A1
WO2017116358A1 PCT/TR2016/050515 TR2016050515W WO2017116358A1 WO 2017116358 A1 WO2017116358 A1 WO 2017116358A1 TR 2016050515 W TR2016050515 W TR 2016050515W WO 2017116358 A1 WO2017116358 A1 WO 2017116358A1
Authority
WO
WIPO (PCT)
Prior art keywords
fatty acid
impedance
albumin
impedance change
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2016/050515
Other languages
English (en)
Inventor
Ismail ORAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2017116358A1 publication Critical patent/WO2017116358A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Definitions

  • drug binding site I (Sudlow site I) (representative ligands are warfarin and phenylbutazone) which is located on subdomain 11 A of the albumin, overlaps with FA7 (fatty acid binding site no.7).
  • drug binding site II (Sodlow site II) (representative ligands are diazepam and propofol) which is located on subdomain IMA of the albumin, overlaps with FA3 and FA4.
  • FA1 also acts as the primary site for binding hemin
  • FA5 is a secondary site for propofol and throxine.
  • FA6 is a secondary site for ibuprofen and diflunisal (Ghuman, J et al.
  • patent application publication no: US 201 1 /0059181 disclosed a methods for hydrophobic drug delivery comprising first producing unfolding albumin which expose its hydrophobic core, then incorporating the drug into the unfolded albumin, and finally obtaining water-soluble drug-albumin complex after allowing refolding of the albumin.
  • the method comprise: providing a sample from patient; determination of fatty acid level in a sample by using impedance measurement carried out by a specific electrolysis reaction.
  • the method also includes adding an albumin ligand(s) in the sample which share(s) same or even common binding sites with fatty acids just before starting electrolysis (and impedance measurement) to displace already bound fatty acid, then providing migration of released fatty acid towards the surface of anode electrode which is strong attractor for fatty acid anions, and defining whether measurement is indicative of acute ischemia or specific medical conditions by comparing the results of normal individuals and/or subject's another sample obtained before adding albumin ligand(s).
  • Example 5 Graphical representation of impedance changes against time in a sample containing OA (sodium oleate) at a concentration of 5mM.
  • OA sodium oleate
  • Example 5 Graphical representation of impedance changes against time during 6 minutes in the same sample (without adding anything) by using four identical but different electrode pairs. Note the rapid upward elevation to reach maximum impedance level for each electrode within 30-45 seconds. Also note the higher the number of electrodes, the lower the level of maximum impedance in each consecutive electrode.
  • Example 6 Graphical representation of impedance changes against time among two different scenarios. The first is the mixture of 0.3ml 5mM OA (sodium oleate) and 0.3ml saline with final OA concentration of 2.5mM. In the second scenario, we prepared 0.3ml CoCI 2 solution in saline at a concentration of 0.02mM. Then we mixed 0.3ml 0.02mM CoCI 2 and 0.3ml 5mM OA with final OA concentration of 2.5mM and final CoCI 2 concentration of 0.01 mM. Note the marked impedance drop in the second scenario; this means that CoCI 2 markedly inhibits reaction occurred in this example.
  • OA sodium oleate

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne un procédé et un appareil de détermination d'acides gras non liés (libres) et/ou de la capacité de liaison d'acides gras de l'albumine en cas d'ischémie grave d'organe/de tissu, ou dans des affections médicales graves/chroniques spécifiques associées à de l'albumine modifiée par des acides gras, et de diagnostic d'affections médicales associées à une augmentation d'acides gras libres et/ou une capacité réduite de liaison aux acides gras de l'albumine dans des échantillons, par mesure d'impédance électrique. Le procédé comprend une réaction d'électrolyse spécifique, dénommée réaction de décarboxylation anodique ou électrolyse de Kolbe, qui se produit sur la surface de l'anode. La réaction se produit entre deux anions d'acides gras et est entraînée par le courant ou potentiel électrique spécifique. Le procédé comprend finalement la condensation de deux anions d'acides gras en une longue molécule d'hydrocarbure sur la surface de l'anode. L'accumulation de nombreuses chaînes d'hydrocarbures crée une couche isolante sur la surface d'anode, ce qui augmente l'impédance électrique entre les électrodes. La variation d'impédance reflète le niveau d'acides gras libres et/ou la capacité de liaison d'acides gras de l'albumine qui est augmenté(e) ou diminué(e) dans les ischémies et/ou les affections médicales spécifiques. L'invention concerne également un appareil comprenant un "instrument" et un "kit à usage unique".
PCT/TR2016/050515 2015-12-28 2016-12-19 Procédé et appareil de détermination de marqueurs d'acides gras par mesure d'impédance électrique Ceased WO2017116358A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201517033 2015-12-28
TR2015/17033 2015-12-28

Publications (1)

Publication Number Publication Date
WO2017116358A1 true WO2017116358A1 (fr) 2017-07-06

Family

ID=57910095

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2016/050515 Ceased WO2017116358A1 (fr) 2015-12-28 2016-12-19 Procédé et appareil de détermination de marqueurs d'acides gras par mesure d'impédance électrique

Country Status (1)

Country Link
WO (1) WO2017116358A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019245507A3 (fr) * 2018-05-17 2020-03-19 Oran Ismail Procédé d'extraction et de détermination d'acide gras dans un fluide biologique
EP4111956A1 (fr) * 2021-07-02 2023-01-04 Samsung Electronics Co., Ltd. Appareil et procédé d'estimation d'informations biologiques sur la base de bio-impédance

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3756928A (en) 1970-08-12 1973-09-04 Basf Ag Ls process for the manufacture of sebacic acid diesters of higher alcoho
US3787299A (en) 1970-03-28 1974-01-22 Basf Ag Electrolytic condensation of carboxylic acids
US3992268A (en) 1974-11-18 1976-11-16 Universal Oil Products Company Hydrocarbon conversion process
US4369250A (en) * 1981-07-31 1983-01-18 Sherwood Medical Industries Inc. Fatty acid determination
US5227307A (en) 1991-07-26 1993-07-13 Diagnostic Markers, Inc. Test for the rapid evaluation of ischemic state
US20020160537A1 (en) 1999-12-08 2002-10-31 Kleinfeld Alan M. Method of detecting cardiac ischemia using fatty acid binding protein
US20050021235A1 (en) 2001-05-30 2005-01-27 Raphael Bar-Or Method and system for optically performing an assay to determine a medical condition
US7063782B2 (en) 2001-11-26 2006-06-20 Ischemia Technologies, Inc. Electrochemical detection of ischemia
WO2007095215A2 (fr) 2006-02-14 2007-08-23 Cps Biofuels, Inc. Fabrication d'essence a partir de charges fermentescibles
US20080161418A1 (en) 2005-03-04 2008-07-03 Markus Dierker Emollients and Cosmetic Compositons Based on Specific Branched Hydrocarbons
US20080305550A1 (en) 2005-01-21 2008-12-11 Hollie Huff Targets for Detection of Ischemia
US20090294304A1 (en) 2004-06-29 2009-12-03 Mark Hyland Electrochemical sensor
US20100291611A1 (en) 2006-02-15 2010-11-18 Inverness Medical Switzerland Gmbh Assays
US20110045520A1 (en) 2007-09-13 2011-02-24 Bhagavan Nadhipuram V Fatty acid markers for the diagnosis, prognosis and management of cardiovascular disease
US20110059181A1 (en) 2009-08-11 2011-03-10 Nanopax Pharma, Llc Methods for drug delivery comprising unfolding and folding proteins and peptide nanoparticles
US20130203953A1 (en) 2009-12-04 2013-08-08 Gonçalo Amarante Guimarães Pereira Method for the production of olefins, an olefin, a polyolefin, and use of the polyolefin
US20140147874A1 (en) 2011-03-04 2014-05-29 The Johns Hopkins University Biomarkers of cardiac ischemia
US20140353163A1 (en) 2009-04-17 2014-12-04 Ion Research, Inc. Biological/Electrolytic Conversion of Biomass to Hydrocarbons

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3787299A (en) 1970-03-28 1974-01-22 Basf Ag Electrolytic condensation of carboxylic acids
US3756928A (en) 1970-08-12 1973-09-04 Basf Ag Ls process for the manufacture of sebacic acid diesters of higher alcoho
US3992268A (en) 1974-11-18 1976-11-16 Universal Oil Products Company Hydrocarbon conversion process
US4369250A (en) * 1981-07-31 1983-01-18 Sherwood Medical Industries Inc. Fatty acid determination
US5227307A (en) 1991-07-26 1993-07-13 Diagnostic Markers, Inc. Test for the rapid evaluation of ischemic state
US5290519A (en) 1991-07-26 1994-03-01 Diagnostic Markers, Inc. Test for the rapid evaluation of ischemic states and kit
US20020160537A1 (en) 1999-12-08 2002-10-31 Kleinfeld Alan M. Method of detecting cardiac ischemia using fatty acid binding protein
US6750030B2 (en) 1999-12-08 2004-06-15 Torrey Pines Institute For Molecular Studies Method of detecting cardiac ischemia using fatty acid binding protein
US20050021235A1 (en) 2001-05-30 2005-01-27 Raphael Bar-Or Method and system for optically performing an assay to determine a medical condition
US20060191788A1 (en) * 2001-11-26 2006-08-31 Ischemia Technologies, Inc. Electrochemical detection of ischemia
US7063782B2 (en) 2001-11-26 2006-06-20 Ischemia Technologies, Inc. Electrochemical detection of ischemia
US20090294304A1 (en) 2004-06-29 2009-12-03 Mark Hyland Electrochemical sensor
US20080305550A1 (en) 2005-01-21 2008-12-11 Hollie Huff Targets for Detection of Ischemia
US20080161418A1 (en) 2005-03-04 2008-07-03 Markus Dierker Emollients and Cosmetic Compositons Based on Specific Branched Hydrocarbons
WO2007095215A2 (fr) 2006-02-14 2007-08-23 Cps Biofuels, Inc. Fabrication d'essence a partir de charges fermentescibles
US20100291611A1 (en) 2006-02-15 2010-11-18 Inverness Medical Switzerland Gmbh Assays
US20110045520A1 (en) 2007-09-13 2011-02-24 Bhagavan Nadhipuram V Fatty acid markers for the diagnosis, prognosis and management of cardiovascular disease
US20140353163A1 (en) 2009-04-17 2014-12-04 Ion Research, Inc. Biological/Electrolytic Conversion of Biomass to Hydrocarbons
US20110059181A1 (en) 2009-08-11 2011-03-10 Nanopax Pharma, Llc Methods for drug delivery comprising unfolding and folding proteins and peptide nanoparticles
US20130203953A1 (en) 2009-12-04 2013-08-08 Gonçalo Amarante Guimarães Pereira Method for the production of olefins, an olefin, a polyolefin, and use of the polyolefin
US20140147874A1 (en) 2011-03-04 2014-05-29 The Johns Hopkins University Biomarkers of cardiac ischemia

Non-Patent Citations (38)

* Cited by examiner, † Cited by third party
Title
AMIRTHARAJ GJ ET AL.: "Fatty acids influence binding of cobalt to serum albumin in patients with fatty liver", BIOCHIMICA BIOPHYSICA ACTA, vol. 1782, 2008, pages 349 - 354, XP022655059, DOI: doi:10.1016/j.bbadis.2008.02.006
ANAND U ET AL.: "Binding, unfolding and refolding dynamics of serum albumin", BIOCHIMICA BIOPHYSICA ACTA, vol. 1830, 2013, pages 5394 - 5404, XP028740273, DOI: doi:10.1016/j.bbagen.2013.05.017
BAL W ET AL.: "Binding of transition metal ions to albumin: Sites, affinities and rates", BIOCHIMICA BIOPHYSICA ACTA, vol. 1830, 2013, pages 5444 - 5455, XP028740276, DOI: doi:10.1016/j.bbagen.2013.06.018
BAR-OR D ET AL.: "A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report", J EMERG MED, vol. 19, 2000, pages 311 - 315
BHAGAVAN NV ET AL.: "Utility of serum fatty acid concentrations as a marker for acute myocardial infarction and their potential role in the formation of ischemia modified albumin: A pilot study", CLIN CHEMISTRY, vol. 55, 2009, pages 1588 - 1590
BLACHE D ET AL.: "Glycated albumin with loss of fatty acid binding capacity contributes to enhance arachidonate oxygenation and platelet hyperactivity: relevance in patients with type 2 diabetes", DIABETES, vol. 64, 2015, pages 960 - 972
BRODERSEN, R. ET AL.: "Multiple fatty acid binding to albumin in human blood plasma", EUR. J. BIOCHEM., vol. 189, 1990, pages 343 - 349
BRUNNER MP: "Effect of heparin administration on metabolomic profiles in samples obtained during cardiac catheterization", CIRC CARDIOVASC GENET, vol. 4, 2011, pages 695 - 700
BRUNO F ET AL.: "Polaromicrotribometric study of a hydrophobic polymer film on platinum electrode during Kolbe electrosynthesis in aqueous media", ELECTROCHIMICA ACTA, vol. 17, 1972, pages 1161 - 1170, XP026507169, DOI: doi:10.1016/0013-4686(72)80001-X
DAVID L TROUT ET AL: "Titration of free fatty acids of plasma: a study of current methods and a new modificati,on*", JOURNAL OF LIPID RESEARCH, 1 January 1960 (1960-01-01), pages 199 - 202, XP055350230, Retrieved from the Internet <URL:http://www.jlr.org/content/1/3/199.full.pdf#page=1&view=FitH> [retrieved on 20170228] *
DESMET R ET AL.: "Heparin-induced release of protein-bound solutes during hemodialysis is an in vitro artifact", CLIN CHEM, vol. 47, 2001, pages 901 - 909
FUJIWARA S ET AL.: "Faty acid binding to serum albumin: Molecular simulation approaches", BIOCHIM BIOPHYSIC ACTA, vol. 1830, 2013, pages 5427 - 5434, XP028740214, DOI: doi:10.1016/j.bbagen.2013.03.032
GAZE DC: "Biomarkers of cardiac ischemia", INTECH, 2013
GHUMAN, J ET AL.: "Structural basis of the drug-binding specificity of human serum albumin", J. MOL. BIOL., vol. 353, 2005, pages 38 - 52, XP005086293, DOI: doi:10.1016/j.jmb.2005.07.075
GV RICHIERI ET AL: "Unbound free fatty acid levels in human serum", JOURNAL OF LIPID RESEARCH, 1 February 1995 (1995-02-01), UNITED STATES, pages 229 - 240, XP055350211, Retrieved from the Internet <URL:http://www.jlr.org/content/36/2/229.full.pdf#page=1&view=FitH> [retrieved on 20170228] *
JALAN R ET AL.: "Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality", HEPATOLOGY, vol. 50, 2009, pages 555 - 564
JUNK MJN ET AL.: "Characterization of the solution structure of human serum albumin loaded with a metal porphyrin and fatty acids", BIOPHYSICAL J, vol. 100, 2011, pages 2293 - 2301, XP028250604, DOI: doi:10.1016/j.bpj.2011.03.050
KIM, JS ET AL.: "Ischemia-Modified Albumin: Is it a reliable diagnostic and prognostic marker for myocardial ischemia in real clinical practice?", CARDIOLOGY, vol. 116, 2010, pages 123 - 129
KIN FONG LEI ET AL: "Real-Time Electrical Impedimetric Monitoring of Blood Coagulation Process under Temperature and Hematocrit Variations Conducted in a Microfluidic Chip", PLOS ONE, vol. 8, no. 10, 7 October 2013 (2013-10-07), pages e76243, XP055088672, DOI: 10.1371/journal.pone.0076243 *
KRENZEL ES ET AL.: "Correspondance of fatty acid and drug binding sites on human serum albumin: A two-dimensional nuclear magnetic resonance study", BIOCHEMISTRY, vol. 52, 2013, pages 1559 - 1567
LU J ET AL.: "Allosteric inhibition of cobalt binding to albumin by fatty acids: Implications for the detection of myocardial ischemia", J MED CHEM, vol. 55, 2012, pages 4425 - 4430
MOROZOV MI: "Ischemia modified albumin as a marker of myocardium and skeletal muscle damage", INT J CARDIOVASC RES, vol. 3, 2014, pages 1 - 5
NELSON PG: "Effect of heparin on serum $A free fatty acids, plasma catecholamines, and the incidence of arrhytmias following acute MI", BRIT MED J, vol. 3, 1970, pages 735 - 737
OH BJ ET AL.: "Insignificant role of the N-terminal cobalt binding site of albumin in the assessment of acute coronary syndrome: Discrepancy between the albumin cobalt binding assay and N-terminal targeted immunoassay", BIOMARKERS, vol. 17, 2012, pages 394 - 401
OPIE LH.: "Metabolism of free fatty acids, glucose and catecholamines in acute myocardial infarction", AM J CARDIOL, vol. 36, 1975, pages 938 - 953, XP023195499, DOI: doi:10.1016/0002-9149(75)90086-7
PETITPAS, I ET AL.: "Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids", J. MOL. BIOL., vol. 314, 2001, pages 955 - 960, XP004473332, DOI: doi:10.1006/jmbi.2000.5208
REZAEI-TAVIRANI M ET AL.: "Conformational study of human serum albumin in predenaturation temperatures by differential scanning calorimetry, circular dichroism and UV spectroscopy", J BIOCHEM MOL BIOL, vol. 39, 2006, pages 530 - 526
RICHIERI GV; KLEINFELD AM: "Unbound free fatty acid levels in human serum", J LIPID RES., vol. 36, 1995, pages 229 - 240, XP055350211
ROGERS WJ: "Effect of heparin-induced free fatty acid elevation on myocardial oxygen consumption in man", AM J CARDIOL, vol. 40, 1977, pages 365 - 372, XP023200692, DOI: doi:10.1016/0002-9149(77)90158-8
RUDMAN D ET AL.: "Effect of free fatty acids on binding of drugs by bovine serum albumin, by human serum albumin and by rabbit serum", PHARMACOL EXP THER, vol. 272, 1971, pages 176 - 261
SCHAFER HJ: "Electrochemical conversion of fatty acids", EUR J LIPID SCI TECHNOL, vol. 114, 2012, pages 2 - 9
SCHAFER HJ: "Recent contributions of Kolbe electrolysis to organic synthesis", TOPICS IN CURRENT CHEMISTRY, vol. 152, 1990, pages 91 - 151
SIMARD JR ET AL.: "Location of high and low affinity fatty acid binding sites on human serum albumin revealed by NMR drug-competition analysis", J MOL BIOL, vol. 361, 2006, pages 336 - 351, XP024951281, DOI: doi:10.1016/j.jmb.2006.06.028
SVADKOVSKAYA GE ET AL.: "Electrolytic condensation of carboxylic acids", RUSSIAN CHEMICAL REVIEWS, vol. 29, 1960, pages 161 - 180, XP009023157, DOI: doi:10.1070/RC1960v029n03ABEH001225
TAYYAB S ET AL.: "Use of domain specific ligands to study urea-induced unfolding of bovine serum albumin", BIOCHEM BIOPHYSIC RES COM, vol. 277, 2000, pages 83 - 88
VIJAY KUMAR ROY ET AL: "Plasma Free Fatty Acid Concentrations as a Marker for Acute Myocardial Infarction", JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, vol. 7, 1 January 2013 (2013-01-01), pages 2432 - 2434, XP055350222, ISSN: 2249-782X, DOI: 10.7860/JCDR/2013/7682.3566 *
WOLFE, R. ET AL.: "Role of triglyceride-fatty acid cycle in controlling fat metabolism in humans during and after exercise", AM. J. PHYSIOL., vol. 258, 1990, pages E382 - E389
YAMAZAKI E ET AL.: "Kinetics of fatty acid binding ability of glycated human serum albumin", J BIOSCI, vol. 30, 2005, pages 475 - 481

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019245507A3 (fr) * 2018-05-17 2020-03-19 Oran Ismail Procédé d'extraction et de détermination d'acide gras dans un fluide biologique
US11892460B2 (en) 2018-05-17 2024-02-06 Ismail ORAN Method for extraction and determination of fatty acid in biological fluid
EP4111956A1 (fr) * 2021-07-02 2023-01-04 Samsung Electronics Co., Ltd. Appareil et procédé d'estimation d'informations biologiques sur la base de bio-impédance

Similar Documents

Publication Publication Date Title
Sun et al. Impaired albumin function: a novel potential indicator for liver function damage?
Inoue et al. Sensitive detection of glycated albumin in human serum albumin using electrochemiluminescence
Wiercinska-Drapalo et al. Intestinal fatty acid binding protein (I-FABP) as a possible biomarker of ileitis in patients with ulcerative colitis
Azzazy et al. Unbound free fatty acids and heart-type fatty acid–binding protein: diagnostic assays and clinical applications
Hasegawa et al. Increased serum resistin levels in patients with type 2 diabetes are not linked with markers of insulin resistance and adiposity
Zhou et al. Ultrasensitive assay of amyloid-beta oligomers using Au-vertical graphene/carbon cloth electrode based on poly (thymine)-templated copper nanoparticles as probes
CN105765382B (zh) 用于预测具有心血管疾病或心血管事件的风险的方法和试剂盒
JP2014532168A (ja) インスリン抵抗性に関連するバイオマーカーおよびそれを使用する方法
Lu et al. Allosteric inhibition of cobalt binding to albumin by fatty acids: implications for the detection of myocardial ischemia
Uygun et al. Fullerene-PAMAM (G5) composite modified impedimetric biosensor to detect Fetuin-A in real blood samples
Zhou et al. Flexible multielectrode arrays based electrochemical aptasensor for glycated human serum albumin detection
Akbay et al. Serum retinol binding protein 4 level is related with renal functions in Type 2 diabetes
Madhurantakam et al. Advancements in electrochemical immunosensors towards point-of-care detection of cardiac biomarkers
Wang et al. Defect-rich CoOOH nanorings: A biocompatible and cost-efficient material for clinical diagnosis of children heart failure
Tan et al. Interaction kinetics of liposome-incorporated unsaturated fatty acids with fatty acid-binding protein 3 by surface plasmon resonance
Castro-Diehl et al. Circulating growth factors and cardiac remodeling in the community: The Framingham Heart Study
ES2535812T3 (es) Homoarginina como un marcador biológico para el riesgo de mortalidad
Hamsten Coagulation factors and hyperlipidaemia
Kaur et al. Enzymatic biosensor platforms for non-infectious diseases: Diagnosis of metabolic disorders
EP4468945A1 (fr) Biomarqueurs pour la détection précoce du diabète
CN115704797B (zh) 基于丝网印刷电极的电化学检测方法
US11892460B2 (en) Method for extraction and determination of fatty acid in biological fluid
Ozbek et al. Serum heart-type fatty acid binding protein levels in acromegaly patients
Arikan et al. N-terminal pro-brain natriuretic peptide in newly diagnosed acromegaly
Tabish Hussain et al. Importance of Cardiac FABP as diagnostic marker of ischaemic heart injury in conjunction with chronic liver disease: A cohort study

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16831650

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16831650

Country of ref document: EP

Kind code of ref document: A1